A Phase 3,Randomized,Open-Label,Multicenter Study to Compare the Efficacy and Safety of BMS-986393,a GPRC5D-directed CAR-T Cell Therapy,Versus Standard Regimens in Adult Participants with Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma
2026-09-14
عنوان الدراسة
A Phase 3,Randomized,Open-Label,Multicenter Study to Compare the Efficacy and Safety of BMS-986393,a GPRC5D-directed CAR-T Cell Therapy,Versus Standard Regimens in Adult Participants with Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma
داعم الدراسة
Celgene Corporation
دواء الدراسة
BMS-986393
رقم بروتوكول الدراسة
CA0881007
حالة الدراسة
Ongoing
موقع الدراسة
1.King Faisal Specialist Hospital and Research Center - Riyadh
مرحلة الدراسة
3
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.